Who is sponsoring NCT04460729?

NCT04460729 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT04460729?

Interventions in NCT04460729: Capmatinib.

What condition does NCT04460729 study?

NCT04460729 studies Non-small Cell Lung Carcinoma (NSCLC).

Is NCT04460729 still recruiting?

NCT04460729 is currently withdrawn. Last updated 3 December 2020.

Last reviewed 2020-12-03 · How we verify

NCT04460729

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Withdrawn Phase 2 Last updated 3 December 2020

What this trial tests

Phase 2 trial testing Capmatinib in Non-small Cell Lung Carcinoma (NSCLC). Withdrawn.

Timeline

11 November 2020

Primary endpoint
17 November 2023

17 November 2023

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	11 November 2020
Primary completion	17 November 2023
Estimated completion	17 November 2023

Drugs / interventions tested

Capmatinib (CAPMATINIB) — full drug profile →

Conditions studied

Non-small Cell Lung Carcinoma (NSCLC) — all drugs for Non-small Cell Lung Carcinoma (NSCLC) →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Non-small Cell Lung Carcinoma (NSCLC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to establish the intracranial efficacy of single agent capmatinib in the population of treatment-naïve or pretreated with one or two prior lines of systemic therapies for advanced stage Non Small-Cell Lung Cancer (NSCLC) with MET exon 14 mutation that has metastasized to the brain. Cohort 1 (asymptomatic brain metastases (BM) without prior brain therapy) has been selected to identify patients who are most likely to benefit from capmatinib therapy in this setting and to establish a clinically relevant response outcome. Cohort 2 is a heterogeneous group of patients (symptomatic with and without prior brain therapy, asymptomatic with prior brain therapy, or with leptomeningeal disease.), and the outcomes will be descriptive only

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Current and future treatment options for <i>MET</i> exon 14 skipping alterations in non-small cell lung cancer.
Hong L, Zhang J, Heymach JV, Le X. · · 2021 · cited 50× · PMID 33643443 · DOI 10.1177/1758835921992976
The progress of microenvironment-targeted therapies in brain metastases.
Long L, Yi Z, Zeng Y, Liu Z. · · 2023 · cited 4× · PMID 37056723 · DOI 10.3389/fmolb.2023.1141994
Recent advances in the treatment of non-small cell lung cancer with MET inhibitors.
Zhang D, Zhang W, Liu H, Liu P, et al · · 2024 · cited 1× · PMID 39720556 · DOI 10.3389/fchem.2024.1501844
Targeting MET in non-small cell lung cancer brain metastases: from molecular mechanism to precision therapy.
Wang X, Chi Y, Mu F, Mao H, et al · · 2026 · PMID 41981677 · DOI 10.1186/s12967-026-08077-2
The global landscape of clinical trials and drug discovery for brain metastasis.
Ding J, Jiang Y, Zhou J, Tang Q, et al · · 2024 · PMID 39107814 · DOI 10.1186/s12967-024-05310-8

Verify or expand the search:

Other trials of Capmatinib

Trials testing the same drug.

NCT06054191 — Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations · Phase 2 · not yet recruiting
NCT05703516 — A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea · recruiting
NCT05642572 — Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A L · Phase 2 · recruiting
NCT05488314 — A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer · Phase 1, PHASE2 · active not recruiting
NCT05243641 — Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients W · Phase 1, PHASE2 · terminated

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04460729 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 3 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04460729.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing